





4º CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2024



CLICaP
Consortio Latinoamericano para la
Investigación del Cáncer de Pulmón

Día 1
26 de febrero 2025

 Dr. Óscar Arrieta México 	 Dr. Francisco Corona México 	 Dra. Enriqueta Felip España 
 Dr. Felipe Couñago España 	 Dr. Juan Carlos Trujillo España 	 Dr. Ernest Nadal España 
 Dr. Luis Seijo España 	 Dr. Iván Bobadilla Colombia 	 Dr. Enric Carcereny España 
 Dra. Renata Baez México 	 Dra. Marian Gómez Aparicio España 	 Dr. Mariano Provencio España 
 Dra. Marisol Arroyo México 	 Dr. Rafael García España 	 Dr. Froylán López México 
 Dra. Lucía Viola Colombia 	 Dr. Néstor Martínez España 	 Dra. Carmen Pupareli Argentina 
 Dr. Sergio Menchaca México 	 Dra. Vanessa Cores México 	 Dr. Diego Lucas Kaen Argentina 
 Dr. Luis Eduardo Pino Colombia 	 Dr. Rami Porta España 	 Dr. Christian Rolfo EU 
 Dr. Alejandro Avilés Salas México 	 Dr. Luis Mas Perú 	 Dra. Francina Bolaños México 
 Dr. Fernando López-Ríos España 	 Dr. Alexandre Martínez España 	 Dr. Enrique Guzmán México 

AstraZeneca 

Roche

SMeO
Sociedad Mexicana de Oncología

CMO
Consejo Mexicano de Oncología

GOECP

SEOR
Sociedad Española de Oncología Radioterápica

CONSEJO MEXICANO DE CERTIFICACIÓN ONCOTERAPIA, A.C.

SECT
Sociedad Española de Cirugía Torácica

ASOC

AAOC
Asociación Argentina de Oncología Clínica

SOMERA
Sociedad Mexicana de Radoterapias

Día 1
26 de febrero 2025

8:00 a.m.  (México)	Bienvenida		Dr. Óscar Arrieta Dr. Felipe Couñago
3:00 p.m.  (España)			
	Cáncer de pulmón: epidemiología y tamizaje		
	Epidemiología y tamizaje	Coordinador: Dr. Luis Seijo	
8:10 a.m.  (México)	A Randomized Controlled Trial of a Digital Lung Health Intervention to Facilitate Smoking Cessation and Lung Cancer Screening WCLC 2024		Dra. Renata Baez
3:10 p.m.  (España)	Impact of Using Smoking Duration in Place of Pack-Years as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities WCLC 2024		
	Triaging Screening Participants At Program Entry: Comparative Performance of PanCan vs LungRADS v1.1 WCLC 2024		
8:20 a.m.  (México)	Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer. ASCO 2024		Dra. Marisol Arroyo
3:20 p.m.  (España)	Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility JCO 2024		
	Lung Cancer Screening Among Individuals with Occupational Exposure: The Fire Health Study		
	Semi-solid lung nodule growth rates, treatments, and cancer-specific verses all-cause mortality in a large North American population		
	Etapificación	Coordinadora: Dra. Lucía Viola	
8:30 a.m.  (México)	Association of FDG-PET CT Findings with sufficient amount of tissue samples for gene panel testing in TBB/TBNA WCLC 2024		Dr. Sergio Menchaca
3:30 p.m.  (España)	Comparative Effectiveness of invasive nodal staging: the importance of guidelines and test sequencing on outcomes WCLC 2024		
	The accuracy of EBUS, EUS, EBUS plus EUS, and mediastinoscopy TBNA WCLC 2024		
	Timing of PET CT has no significant impact on staging EBUS results in mediastinal staging and diagnosis of lung cancer TBNA WCLC 2024		
	Tamizaje e inteligencia artificial	Coordinador: Dr. Luis Seijo	
8:40 a.m.  (México)	Predicting Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced NSCLC with Machine Learning and CT Radiomics WCLC 2024		Dr. Luis Eduardo Pino
3:40 p.m.  (España)	Deep Multiple Instance Learning-enabled Gene Mutation Prediction of Lung Cancer from Histopathology Images WCLC 2024		
	Artificial Intelligence-Based Model for Personalized Immunotherapy in Patients with Early-Stage NSCLC Treated with Stereotactic Ablative Radiotherapy: I-SABR SELECT WCLC 2024		
8:50 a.m.  (México)	Discusión		Todos
3:50 p.m.  (España)			



	Patología	Dr. Alejandro Avilés Salas
9:00 a.m.  (México)	Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung01 WCLC 2024	
4:00 p.m.  (España)	Prognostic Impact of Non-Predominant Lepidic Components in Pathologic Stage I Invasive Nonmucinous Adenocarcinoma	Dr. Fernando López-Ríos
	The relevance of the reference range for EGFR testing in non-small cell lung cancer patients	
9:10 a.m.  (México)	Discusión	Todos
4:10 p.m.  (España)		
	Cáncer de pulmón en etapas tempranas: Cirugía	
	Cirugía	Coordinador: Dr. Francisco Corona
9:20 a.m.  (México)	Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC JTO 2024	
4:20 p.m.  (España)	Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial JTO 2024	Dr. Juan Carlos Trujillo
	Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion A Secondary Analysis of a Randomized Clinical Trial JAMA Oncol 2024	
	Surgical outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis. ASCO 2024	
	Radioterapia en etapa temprana	Coordinador: Dr. Iván Bobadilla
9:30 a.m.  (México)	Neoadjuvant Concurrent Chemo-immuno- Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT trial (WJOG 12119L) WCLC 2024	Dra. Marian Gómez Aparicio
4:30 p.m.  (España)	Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study	
9:40 a.m.  (México)	Real-world acute toxicity and 90-day mortality in patients with stage I NSCLC treated with stereotactic body radiotherapy	
4:40 p.m.  (España)	Climate impact of early-stage NSCLC treatment: A comparison between radiotherapy and surgery using Life Cycle Assessment	Dr. Rafael García
	Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial	
	Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results	
9:50 a.m.  (México)	Discusión	Todos
4:50 p.m.  (España)		
	Mesa de debate	Coordinador: Dr. Néstor Martínez
10:00 a.m.  (México)	SBRT vs. Tratamiento quirúrgico en enfermedad temprana	Dr. Felipe Couñago
5:00 p.m.  (España)		Dra. Vanessa Cores

Neoadyuvancia/Adyuvancia CPCNP no mutados		Coordinador: Dr. Ramí Porta	
Actualizaciones en el tratamiento sistémico neoadyuvante en CPCNP resecable			
10:20 a.m.  (México) 5:20 p.m.  (España)	Perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816 WCLC 2024 Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase II POTENTIAL study ESMO 2024 Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN. ASCO 2024 Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. ASCO 2024 Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis Neoadjuvant Chemoimmunotherapy for NSCLC A Systematic Review and Meta-Analysis	Dr. Óscar Arrieta	
	Nuevas opciones de tratamiento sistémico neoadyuvante en CPCNP resecable (Otros ICIs, antiangiogénicos)		
	10:40 a.m.  (México) 5:40 p.m.  (España)	A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer WCLC 2024 Association of Pathologic Regression With Event-Free Survival in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC WCLC 2024 LBA1532: Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: additional analysis and extended follow-up WCLC 2024 NeoCOAST-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC WCLC 2024 Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159 ESMO 2024 Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)	Dr. Luis Mas
		Actualizaciones de estudios de adyuvancia en pacientes no mutados	
		11:00 a.m.  (México) 6:00 p.m.  (España)	IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIa NSCLC WCLC 2024 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC) ESMO 2024
11:10 a.m.  (México) 6:10 p.m.  (España)			Discusión
11:20 a.m.  (México) 6:20 p.m.  (España)	BREAK		

Mesa de debate		Coordinadora: Dra. Enriqueta Felip
11:30 a.m.  (México)	Tratamiento neoadyuvante vs. perioperatorio CNPCNP resecable	Dr. Ernest Nadal Dr. Enric Carcereny
6:30 p.m.  (España)		
Conferencia magistral		
12:00 p.m.  (México)	Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial	Dr. Mariano Provencio
7:00 p.m.  (España)		
Tratamiento sistémico en la enfermedad no metastásica en pacientes EGFR/ALK		Coordinador: Dr. Froylán López
12:30 p.m.  (México)	Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. ASCO 2024	Dra. Carmen Pupareli
7:30 p.m.  (España)	Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study ESMO 2024	
	ALINA safety results: adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC) WCLC 2024	
12:40 p.m.  (México)	ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo) ESMO 2024	Dr. Diego Lucas Kaen
7:40 p.m.  (España)	Aumolertinib after Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer with EGFR Mutation: Interim Analysis of the Phase III POLESTAR Study WCLC 2024	
	Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC). ASCO 2024	
	Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC	
12:50 p.m.  (México)	Discusión	Todos
7:50 p.m.  (España)		
Conferencia magistral Papel de biopsia líquida en etapa temprana y localmente avanzada		
1:00 p.m.  (México)	Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer WCLC 2024	Dr. Christian Rolfo
8:00 p.m.  (España)	Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN ESMO 2024	
	Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial ESMO 2024	
	ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months. ASCO 2024	
	Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). ASCO 2024	
	Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC	
	Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non–Small Cell Lung Cancer A Nonrandomized Controlled Trial	

4^o CONGRESO IBEROAMERICANO:
Lo mejor en Cáncer de Pulmón 2024



Mesa de debate		Coordinador: Dr. Francisco Corona
1:30 p.m.  (México)	El manejo quirúrgico posterior a quimioinmunoterapia neoadyuvante	Dra. Francina Bolaños Dr. Enrique Guzmán
8:30 p.m.  (España)		
1:50 p.m.  (México)	CIERRE DÍA 1	Dr. Felipe Couñago
8:50 p.m.  (España)		



4º CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2024



CLICaP
Consorcio Latinoamericano para la
Investigación del Cáncer de Pulmón

Día 2

27 de febrero 2025

 Dr. Óscar Arrieta México 	 Dr. David Dávila México 	 Dra. Laura Mezquita España 
 Dr. Federico Maldonado México 	 Dr. Jesús García-Foncillas España 	 Dr. Javier de Castro España 
 Dra. Daniela Gonsalves España 	 Dr. Delvys Rodríguez España 	 Dr. Mauricio Cuello Uruguay 
 Dr. David Vicente Baz España 	 Dr. José Luis González Larriba España 	 Dra. Narjust Florez Venezuela 
 Dr. Carlos Aliaga Perú 	 Dr. Enrique Caballé México 	 Dr. Víctor Oyervides México 
 Dr. Jesús Corral España 	 Dr. Luis Raez Perú 	 Dr. Luis Cancel México 
 Dr. Abrahams Ocanto España 	 Dra. Rosario García Campelo España 	 Dr. Rafael Rosell España 
 Luis Corrales Costa Rica 	 Dr. Rafael López España 	 Dr. Luis Lara México 
 Dra. Esther Holgado España 	 Dr. Edgar Varela México 	 Dra. Tania Soria Ecuador 
 Dr. Leonardo Rojas Colombia 	 Dr. Marco Gálvez Niño Perú 	 Dr. Felipe Couñago España 
 Dr. Claudio Marín Argentina 	 Dr. Ludwing Bacon Fonseca Nicaragua 	

AstraZeneca 

Roche

Día 2 27 de febrero 2025

8:00 a.m.  (México)	Bienvenida	Dr. Óscar Arrieta
3:00 p.m.  (España)	CPCNP localmente avanzado irresecable	Coordinador: Dr. Federico Maldonado
	Actualidades en el manejo de la enfermedad localmente avanzada	
8:10 a.m.  (México)	Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R ESMO Open 2024 A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914 ESMO 2024 Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee JTO 2024	Dra. Daniela Gonsalves
3:10 p.m.  (España)	Primary Results of NRG-RT0G1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo) Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Position Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer JCO 2024 Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer A Secondary Analysis of a Randomized Clinical Trial JAMA	
	Intensificación de tratamiento en enfermedad localmente avanzada	
8:25 a.m.  (México)	Atezolizumab + induction chemotherapy (Ch) + chemo-radiotherapy (Ch-RT) and atezolizumab maintenance in non-resectable stage IIIA-IIIB-IIIC non-small cell lung cancer (NSCLC): APOLO trial WCLC 2024 Intensified chemo-immuno-radiotherapy with durvalumab for stage III NSCLCs: a single arm phase II study – PACIFIC-BRAZIL (LACOG 2218) WCLC 2024	Dr. David Vicente Baz
3:25 p.m.  (España)	A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). ASCO 2024 Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer A Phase II Nonrandomized Controlled Trial JAMA 2024	
8:40 a.m.  (México)	Discusión	Todos
3:40 p.m.  (España)	Mesa de Debate	Coordinador: Dr. Carlos Aliaga
8:50 a.m.  (México)	El manejo de la enfermedad N2: tratamiento quirúrgico vs. quimiorradioterapia	Dr. Jesús Corral Dr. Abrahams Ocantó
3:50 p.m.  (España)		

CPCNP avanzado no mutados		Coordinador: Luis Corrales
Actualizaciones en el manejo de la enfermedad metastásica sin drivers oncogénicos		
9:20 a.m.  (México)	Cemiplimab monotherapy for first line advanced NSCLC patients with PD-L1 expression $\geq 50\%$: 5-year outcomes of EMPOWER-Lung 1 WCLC 2024	Dra. Esther Holgado
4:20 p.m.  (España)	Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeerR): A phase Ib/Ia clinical trial targeting identified resistance pathways ESMO 2024	
	Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial ESMO 2024	
	Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression $\geq 25\%$: Results from the Randomized Phase 3 PEARL Study	
9:30 a.m.  (México)	Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥ 70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study	Dr. Leonardo Rojas
4:30 p.m.  (España)	Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial	
	Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up	
	Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naïve advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial	
	Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer	
Nuevas opciones terapéuticas en el manejo de la enfermedad metastásica sin drivers oncogénicos (Antiangiogénicos, nuevos ICIs, iPARPs)		
9:45 a.m.  (México)	Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up WCLC 2024	Dr. Claudio Marín
4:45 p.m.  (España)	Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1–49% or $\geq 50\%$ WCLC 2024	
	Volrustomig + platinum doublet chemotherapy in first-line non-small-cell lung cancer (NSCLC): Phase 1b trial update WCLC 2024	
	Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1- positive Advanced NSCLC: HARMONI-2 WCLC 2024	
9:55 a.m.  (México)	Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS $\geq 50\%$) non-small cell lung cancer (NSCLC) ESMO 2024	
4:55 p.m.  (España)	LBA53 - Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study ESMO 2024	
	Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non–Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy	
	Efficacy and safety of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, plus chemotherapy in patients with stage IV NSCLC	
10:05 a.m.  (México)	Discusión	Todos
5:05 p.m.  (España)		

	Mesa de debate	Coordinador: Luis Corrales
10:15 a.m.  (México)	El papel de la adición del anti CTLA-4 en el tratamiento de la enfermedad metastásica sin drivers oncogénicos	Dr. David Dávila Dr. Jesús García-Foncillas
5:15 p.m.  (España)		
	ADCs en CPCNP sin alteraciones genómicas accionables	
10:40 a.m.  (México)	Saffron-301: Tislelizumab Plus Sitravatinib In Advanced/Metastatic NSCLC Progressing On/After Chemotherapy And Anti–PD-(L)1 WCLC 2024	Dr. Delvys Rodríguez
	Datopotamab Deruxtecan vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01 WCLC 2024	
	Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial WCLC 2024	
	5:40 p.m.  (España)	Sacituzumab Govitecan vs Docetaxel in Patients With mNSCLC Non-Responsive to Last Anti-PD-(L)1–Containing Regimen: EVOKE-01 WCLC 2024
	Telisotuzumab Vedotin in Asian Patients With c-Met Protein–Overexpressing Non-Squamous EGFR WT NSCLC: Results From LUMINOSITY WCLC 2024	
	Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study WCLC 2024	
	ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. ASCO 2024	
10:45 a.m.  (México)	Discusión	Todos
5:45 p.m.  (España)		
	CPCNP avanzado: EGFR	Coordinador: Dr. Enrique Caballé
	Anticuerpos biespecíficos	
10:55 a.m.  (México)	Ami + Laz in Amivantamab Plus Lazertinib vs Osimertinib 1L EGFR+ NSCLC in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study WCLC 2024	Dr. Luis Raez
	Lazertinib vs Osimertinib in 1L EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA WCLC 2024	
	Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. ASCO 2024	
	Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study ESMO 2024	
5:55 p.m.  (España)	Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study. ASCO 2024	
	Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2 ESMO 2024	

Antiangiogénicos, quimioterapia y terapia dirigida	
11:10 a.m.  (México) 6:10 p.m.  (España)	Osimertinib with or without Savolitinib as 1L in de novo MET aberrant, EGFRm advanced NSCLC (CTONG 2008, FLOWERS): A Phase II trial WCLC 2024 A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum–Pemetrexed Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial Dra. Rosario García Campelo
Uso de inmunoterapia en enfermedad EGFR	
11:20 a.m.  (México) 6:20 p.m.  (España)	Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis Lancet Oncol 2024 Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONI-A): A randomized, double-blind, multi-center, phase 3 trial. ASCO 2024 Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer JCO 2024 Dr. Rafael López
Discusión con los expertos	
11:30 a.m.  (México) 6:30 p.m.  (España)	Coordinador: Dr. José Luis González Larriba Eligiendo la mejor primera línea en enfermedad EGFR avanzada Combos vs. monoterapia Dr. Luis Raez Dr. Rafael López TBC
Manejo de la enfermedad EGFR con mutaciones no comunes	
11:50 a.m.  (México) 6:50 p.m.  (España)	Coordinador: Dr. Edgar Varela FURTHER (FURMO-002): A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI- Naïve, Advanced NSCLC with EGFR PACC Mutations WCLC 2024 Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2. ASCO 2024 Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab ESMO 2024 A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study. ASCO 2024 Dr. Marco Gálvez Niño
ADCs en CPCNP con alteraciones genómicas accionables	
12:00 p.m.  (México) 7:00 p.m.  (España)	Coordinador: Dr. Edgar Varela HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) Dr. Ludwig Bacon Fonseca

CPCNP Avanzado: ALK/ROS1		Coordinadora: Dra. Laura Mezquita
12:10 p.m.  (México)	Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. ASCO 2024 Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons Randomized, Open-label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) WCLC 2024 Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours ESMO 2024	Dr. Javier de Castro
7:10 p.m.  (España)		
12:25 p.m.  (México)	Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours ESMO 2024 Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial. ASCO 2024 Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non-small cell lung cancer: The phase 2 TRUST-I study. ASCO 2024	Dr. Mauricio Cuello
7:25 p.m.  (España)	Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study	
12:40 p.m.  (México)	Discusión	Todos
7:40 p.m.  (España)		
Conferencia magistral		
12:50 a.m.  (México)	ALK	Dra. Narjust Florez
7:50 p.m.  (España)		
CPCNP Avanzado: KRAS		Coordinador: Dr. Víctor Oyervides
1:20 p.m.  (México)	KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ASCO 2024 Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study WCLC 2024 KRAS G12C inhibitor IBI351 in patients with advanced non-small cell lung cancer (NSCLC): updated results from a pivotal phase 2 study WCLC 2024 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC WCLC 2024	Dr. Luis Cancel
8:20 p.m.  (España)	Divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC WCLC 2024 Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors: An individual patient meta-analysis ESMO 2024 Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC	
1:40 p.m.  (México)	Discusión	Todos
8:40 p.m.  (España)		

	CPCNP otros drivers	Coordinadora: Dra. Tania Soria
1:50 p.m.  (México) 8:50 p.m.  (España)	Preliminary Results from A FIH Study of GQ1005, A Novel HER2-ADC, in Patients with Advanced HER2-expressing Solid Tumors And HER2-mutated NSCLC WCLC 2024 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-small Cell Lung Cancer: DESTINY-Lung03 Part 1 Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study WCLC 2024 Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data. ASCO 2024 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC) ESMO 2024 Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF) ESMO 2024 Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors	Dr. Luis Lara Dr. Rafael Rosell
1:10 p.m.  (México) 8:10 p.m.  (España)	Discusión	Todos
1:20 p.m.  (México) 8:20 p.m.  (España)	CIERRE DE JORNADA	Dr. Felipe Couñago

4º CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2024



CLICaP
Consortio Latinoamericano para la
Investigación del Cáncer de Pulmón

Día 3

28 de febrero 2025

 Dr. Óscar Arrieta México 	 Dra. Laura Mezquita España 	 Dr. Luis Paz-Ares España 
 Dra. Daniela Gonsalves España 	 Dra. Mónica Blake México 	 Dra. Pamela Soberanis México 
 Dra. Margarita Martín España 	 Dr. Jorge Palazzo Argentina 	 Dr. José Ángel García Cuesta España 
 Dr. Felipe Couñago España 	 Dr. Rodolfo Chicas España 	 Dra. Dolores Isla España 
 Dr. Francisco Lozano México 	 Dr. José Luis López Guerra España 	 Dra. Laura Bolaño Guerra México 
 Dra. Virginia Calvo España 	 Dra. Lijia Avilés Bolivia 	 Dr. Marco A. Iñiguez García México 
 Dr. Gustavo Ferraris España 	 Dr. Arturo Navarro España 	 Dr. Víctor Duque España 
 Dra. Paloma Sosa Fajardo España 	 Dr. Máximo Barros Argentina 	 Dr. Suraj Samtani Chile 
 Dr. Andrés Cardona Colombia 	 Dra. Nuria Rodríguez de Dios España 	 Dr. Xabier Mielgo España 
 Dr. Bernardo Cacho México 	 Dr. Luis Cabrera México 	 Dr. Mariano Provencio España 
 Dra. Dolores de la Mata México 	 Dr. Santiago Ponce España 	

AstraZeneca 

Roche

SMEO

CMO
Consejo Mexicano de Oncología

GOECP

SEOR
Sociedad Española de
Oncología Radioterápica

CONSEJO MEXICANO
DE CERTIFICACIÓN
ONCOTERAPIA, A.C.

SECT
SOCIEDAD ESPAÑOLA
DE CIRUGÍA
TORÁCICA

ASOCIACIÓN ARGENTINA
DE ONCOLOGÍA CLÍNICA

AAOC
ASOCIACIÓN ARGENTINA
DE ONCOLOGÍA CLÍNICA

SOMERA
Sociedad Mexicana de Radoterapias

Día 3
28 de febrero 2025

8:00 a.m.  (México) 3:00 p.m.  (España)	Bienvenida	Dr. Óscar Arrieta
CPCNP: Radioterapia en enfermedad avanzada		
Radioterapia en enfermedad avanzada		Coordinadora: Dra. Daniela Gonsalves
8:10 a.m.  (México) 3:10 p.m.  (España)	Ablation to oligo-residual sites plus ICIs improved survival of patients with advanced NSCLC : preliminary results of the phase II BOOSTER trial WCLC 2024 Radiotherapy improves survival in NSCLC following oligoprogression on immunotherapy: A cohort study WCLC 2024 Pulsed High-Dose Fractionated Radiotherapy Combined with Enhanced Immunotherapy for Driver Gene-Negative Advanced Non-small-cell Lung Cancer: A Clinical Study WCLC 2024 NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). ASCO 2024 Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial. ASCO 2024 Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial JCO 2024 Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial	Dra. Margarita Martín
8:20 a.m.  (México) 3:20 p.m.  (España)	Discusión	Todos
Mesa de debate		Coordinador: Dr. Felipe Couñago
8:30 a.m.  (México) 3:30 p.m.  (España)	Tratamiento local para el CPCNP oligometastático y oligoprogresivo	Dr. Francisco Lozano Dra. Virginia Calvo
Radioterapia en el manejo de la enfermedad metastásica a SNC		Coordinador: Dr. Gustavo Ferraris
8:50 a.m.  (México) 3:50 p.m.  (España)	Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC) Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060 Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs WCLC 2024	Dra. Paloma Sosa Fajardo

9:00 a.m.  (México) 4:00 p.m.  (España)	Discusión	Todos
	Discusión con los expertos	Coordinador: Dr. Andrés Cardona
9:10 a.m.  (México) 4:10 p.m.  (España)	Manejo multidisciplinario de la enfermedad metastásica a SNC en CPCNP	Dr. Bernardo Cacho Dra. Dolores de la Mata Dra. Laura Mezquita
	Discusión con los expertos	
9:40 a.m.  (México) 4:40 p.m.  (España)	Actualidades en el diagnóstico y tratamiento de la radionecrosis	Dr. Andrés Cardona Dra. Mónica Blake
	ASTRO/ESTRO	Coordinador: Dr. Jorge Palazzo
	Lo mejor de ASTRO 2024	
10:00 a.m.  (México) 5:00 p.m.  (España)	Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005 Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs) Neurocognitive Outcome of Conformal Whole Brain Radiotherapy with Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiotherapy for Oligometastatic Disease: A Secondary Analysis of the Phase II SABR-5 Trial I-SABR-SELECT: A Radiomics-Based Model for Personalized Immunotherapy for Early-Stage Non-Small Cell Lung Cancer	Dr. Rodolfo Chicas
	Lo mejor de ESTRO 2024	
10:10 a.m.  (México) 5:10 p.m.  (España)	A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic non-small cell lung cancer SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial. SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma Efficacy and toxicity of moderately hypofractionated radiotherapy via helical tomotherapy versus conventional radiotherapy combined with concurrent chemotherapy for patients with unresectable stage III non-small cell Lung Cancer: a multicenter, randomized phase III trial	Dr. José Luis López Guerra
10:20 a.m.  (México) 5:20 p.m.  (España)	Discusión	Todos

	Mesa manejo de carcinoma (enfermedad limitada)	Coordinadora: Dra. Lijia Avilés
10:30 a.m.  (México)	ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). ASCO 2024	Dr. Arturo Navarro
5:30 p.m.  (España)	Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial ESMO 2024	
10:40 a.m.  (México)	Discusión	Todos
5:40 p.m.  (España)		
	Mesa de debate	Coordinadora: Dra. Dolores de la Mata
10:50 a.m.  (México)	Irradiación craneal profiláctica en CPCP: ¿debemos seguir haciéndola?	Dr. Máximo Barros Dra. Nuria de Dios
5:50 p.m.  (España)		
11:10 a.m.  (México)	BREAK	
6:10 p.m.  (España)		
	Tratamiento sistémico en CPCP	
	Primera línea	Coordinador: Dr. Luis Cabrera
11:20 a.m.  (México)	Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of IDEate-Lung01 WCLC 2024	Dr. Santiago Ponce Dr. Luis Paz-Ares
6:20 p.m.  (España)	SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced small-cell lung cancer (SCLC) WCLC 2024	
	Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-Up WCLC 2024	
	Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance After Chemo-Immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study WCLC 2024	
	Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T-Cell Engager, in Small Cell Lung Cancer WCLC 2024	
	Sacituzumab Govitecan as Second-Line Treatment in Patients With Extensive-Stage Small Cell Lung Cancer WCLC 2024	
	BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study ESMP 2024	
	Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. ASCO 2024	
	BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). ASCO 2024	
	Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929	
	Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial	
	Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study	

11:40 a.m.  (México)	Discusión	Todos
6:40 p.m.  (España)	Mesotelioma	
	Primera línea	Coordinadora: Dra. Pamela Soberanis
11:50 a.m.  (México)	PEMBrolizumab Plus Lenvatinib In Second-Line Pleural MEsotheLioma Patients: a Single Arm Phase II Study – PEMMELA (second cohort) WCLC 2024 Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial. ASCO 2024 BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial. ASCO 2024 Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study. ASCO 2024 Real-world outcomes of patients with malignant pleural mesothelioma receiving combination ipilimumab and nivolumab as first- or later line treatment	Dr. José Ángel García Cuesta Dra. Dolores Isla
6:50 p.m.  (España)		
12:10 p.m.  (México)	Discusión	Todos
7:10 p.m.  (España)	Mesa de Debate	Coordinadora: Dra. Laura Bolaño Guerra
12:20 p.m.  (México)	Papel de la radioterapia y cirugía en mesotelioma	Dr. José Ángel García Cuesta Dr. Marco A. Iñiguez García Dr. Víctor Duque
7:20 p.m.  (España)		
	Timoma y carcinoma tímico	Coordinador: Dr. Suraj Samtani
12:40 p.m.  (México)	Real-world data on the efficacy and safety of lenvatinib in patients with previously treated thymic carcinoma WCLC 2024 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma ESMO 2024 Clinical Characteristics and Outcomes of Patients with Thoracic SMARCA4-deficient Undifferentiated Tumors WCLC 2024	Dr. Xabier Mielgo
7:40 p.m.  (España)	First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation ESMO 2024 S1701, A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma	
1:10 p.m.  (México)	Discusión	Todos
8:10 p.m.  (España)		

Actualización Estudios 2024: España y Latinoamérica		Coordinadores: Dr. Óscar Arrieta Dr. Felipe Couñago
Actualización Estudios 2024: España		
1:20 p.m.  (México) 8:20 p.m.  (España)	Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial Certification system for multidisciplinary thoracic tumour boards Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry RET Fusion Testing in Patients With NSCLC: The RETING Study Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients Difficulties on the access to innovative targeted therapies for lung cancer in Spain Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer	Dr. Mariano Provencio
Actualización Estudios 2024 Latinoamérica		
1:50 p.m.  (México) 8:50 p.m.  (España)	Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study. Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial. Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients. Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM). Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.	Dr. Andrés Cardona
2:20 p.m.  (México) 8:20 p.m.  (España)	Discusión	Todos
2:55 p.m.  (México) 9:55 p.m.  (España)	Despedida y Cierre	Dr. Óscar Arrieta Dr. Felipe Couñago